Trials / Completed
CompletedNCT00738764
A Trial of PDL192 in Subjects With Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
Detailed description
The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PDL192 | Humanized anti-TWEAK receptor monoclonal IgG1 antibody |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-08-20
- Last updated
- 2012-01-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00738764. Inclusion in this directory is not an endorsement.